Change over period: —
NSE · CAPLIPOINT
CAPLIPOINT
-27.3% from the 52-week high · +38.6% above the low
Caplin Point Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Chennai, Tamil Nadu and currently employs 777 full-time employees. The firm is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). The company also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. The company has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
The short version. CAPLIPOINT reported revenue of ₹630 crore for Sep 2026, up 18.0% from a year earlier. Net profit was ₹178 crore (up 15.6% year on year). Return on equity was 17.9% in Mar 2026. Promoter holding was 70.57% in Sep 2026, up 0.01 points over 8 quarters.
1 · The price
How has the stock traded?
CAPLIPOINT trades 27.3% below its 52-week high and 38.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹630 cr.
Sep 2026 net profit of ₹178 cr.
0.6 pts lower than a year earlier.
Revenue compounded at 14.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 630 | 610 | 600 | 543 | 534 | 510 | 502 | 493 |
| Net profit | 178 | 177 | 170 | 164 | 154 | 153 | 143 | 139 |
| Net margin % | 28.3 | 29.0 | 28.3 | 30.2 | 28.9 | 29.9 | 28.4 | 28.2 |
| EPS (₹) | 23.43 | 23.27 | 22.38 | 21.56 | 20.32 | 20.1 | 18.76 | 18.28 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2187 | 1937 | 1694 | 1467 | 1269 | 1061 | 863 | 649 |
| Net profit | 641 | 536 | 457 | 376 | 308 | 242 | 215 | 177 |
| Net margin % | 29.3 | 27.7 | 27.0 | 25.7 | 24.3 | 22.8 | 24.9 | 27.2 |
| EPS (₹) | 84.36 | 70.56 | 60.19 | 49.57 | 40.7 | 32.03 | 28.42 | 23.35 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 17.9% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 17.9 | 18.8 | 19.7 | 20.0 |
| Return on capital % | 22.0 | 23.3 | 23.9 | 23.5 |
| EBITDA margin % | 38.1 | 36.5 | 35.1 | 32.6 |
| Net margin % | 27.9 | 26.4 | 26.0 | 24.7 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 14.8% | 16.2% |
| Profit CAGR | 19.4% | 21.5% |
4 · The owners
Who holds it, and are they adding?
Up 0.01 pts over 8 quarters.
Up 0.87 pts over 8 quarters.
Up 0.09 pts over 8 quarters.
+16 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.56 | 70.56 | 70.56 | 70.57 | 70.57 | 70.57 | 70.57 | 70.57 | +0.01 |
| FII | 4.86 | 5.73 | 6.17 | 6.51 | 6.59 | 6.15 | 5.75 | 5.73 | +0.87 |
| DII | 2.11 | 2.01 | 2.22 | 2.1 | 2.05 | 2.14 | 2.49 | 2.2 | +0.09 |
| Public | 22.47 | 21.7 | 21.05 | 20.82 | 20.79 | 21.14 | 21.18 | 21.5 | -0.97 |
Mutual fund holdings · Oct 2026
67 schemes hold this stock
51 the month before.
- UTI - Healthcare Fund2.68% of NAV
- THE WEALTH COMPANY SMALL CAP FUND1.7% of NAV
- THE WEALTH COMPANY BALANCED ADVT FUND1.64% of NAV
- UTI Small Cap Fund1.61% of NAV
- the Quantum Small Cap Fund1.56% of NAV
- UTI Large & Mid Cap Fund0.93% of NAV
- UTI Aggressive Hybrid Fund0.7% of NAV
- Groww Nifty Smallcap 250Mom Qlty 100 ETF0.64% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for CAPLIPOINT are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about CAPLIPOINT
What is the CAPLIPOINT share price?
CAPLIPOINT (CAPLIPOINT) last closed at ₹2,091.50, up 0.3% on the day. Its 52-week range is ₹1,504.80 to ₹2,867.40.
What is the market cap of CAPLIPOINT?
CAPLIPOINT has a market capitalisation of about ₹15,853 crore. Its price-to-earnings ratio is 23.1.
How are CAPLIPOINT's latest results?
CAPLIPOINT reported revenue of ₹630 crore for Sep 2026, up 18.0% from a year earlier. Net profit was ₹178 crore (up 15.6% year on year). Return on equity was 17.9% in Mar 2026. Promoter holding was 70.57% in Sep 2026, up 0.01 points over 8 quarters.
Who owns CAPLIPOINT?
As of Sep 2026, shareholding was: Promoter 70.57%, FII 5.73%, DII 2.2%, Public 21.5%.
How many mutual funds hold CAPLIPOINT?
67 mutual fund schemes held CAPLIPOINT in October 2026. That compares with 51 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 29 May 2026 · Interim Dividend - Rs. 4
- 12 Sep 2025 · Final Dividend - Rs. 3
- 30 May 2025 · Interim Dividend - Rs. 3
- 23 Sep 2024 · Final Dividend - Rs. 2.5
- 31 May 2024 · Interim Dividend - Rs. 2.5
- 14 Sep 2023 · Final Dividend - Rs. 2.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.